Blood serum levels of PACAP and migraine onset: A systematic review and meta-analysis of observational studies
- PMID: 38659322
- DOI: 10.1111/head.14711
Blood serum levels of PACAP and migraine onset: A systematic review and meta-analysis of observational studies
Abstract
Objective: We conducted a systematic review and meta-analysis to explore the relationship between blood pituitary adenylate cyclase-activating polypeptide (PACAP) levels and migraine.
Background: PACAP is involved in the onset of migraine, but the results from clinical studies on PACAP level variations across different periods of migraine are conflicting.
Methods: We systematically searched for observational studies that reported PACAP levels in people with migraine and non-migraine controls published in English from the PubMed, Web of Science, and Ovid electronic databases, or in Chinese from the Chinese National Knowledge Infrastructure and the WanFang Med database. The Newcastle-Ottawa Quality Assessment Scale was used to assess the quality of the included studies. The quality of evidence for each outcome was assessed according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) guidelines.
Results: Of the 514 identified studies, 8 were eligible for inclusion. There was a "very low" level of evidence suggesting that the PACAP level is negatively correlated with migraine disease duration in adults with migraine (summary = -0.35, 95% confidence interval [CI] -0.49 to -0.22) and that the PACAP is higher in people with migraine during the ictal period than in the interictal period (standardized mean difference = 0.41, 95% CI 0.17 to 0.66) for both adults and children with migraine. Adult patients with episodic migraine (weighted mean difference [WMD] = -9.58 pg/mL, 95% CI -13.41 to -5.75 pg/mL) or chronic migraine (WMD = -10.93 pg/mL, 95% CI -15.57 to -6.29 pg/mL) had lower blood PACAP levels than non-migraine controls during the interictal period, supported by a "low" or "very low" quality of evidence, respectively, according to the GRADE rules.
Conclusion: There is a very low certainty of evidence suggesting that the PACAP level is negatively correlated with migraine disease duration of adults with migraine and it varies greatly among different periods of migraine of both adults and children with migraine.
Keywords: chronic migraine; episodic migraine; meta‐analysis; observational study; pituitary adenylate cyclase‐activating polypeptide; systematic review.
© 2024 American Headache Society.
Similar articles
-
Interictal plasma pituitary adenylate cyclase-activating polypeptide levels are decreased in migraineurs but remain unchanged in patients with tension-type headache.Clin Chim Acta. 2015 Oct 23;450:151-4. doi: 10.1016/j.cca.2015.08.017. Epub 2015 Aug 19. Clin Chim Acta. 2015. PMID: 26296898
-
Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice.Mol Biol Rep. 2020 Sep;47(9):7125-7138. doi: 10.1007/s11033-020-05781-0. Epub 2020 Sep 20. Mol Biol Rep. 2020. PMID: 32951099 Clinical Trial.
-
No Change in Interictal PACAP Levels in Peripheral Blood in Women With Chronic Migraine.Headache. 2016 Oct;56(9):1448-1454. doi: 10.1111/head.12949. Epub 2016 Sep 16. Headache. 2016. PMID: 27634731
-
Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review.Expert Opin Investig Drugs. 2020 Nov;29(11):1269-1275. doi: 10.1080/13543784.2020.1811966. Epub 2020 Sep 2. Expert Opin Investig Drugs. 2020. PMID: 32877252 Review.
-
Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine.J Headache Pain. 2018 May 21;19(1):35. doi: 10.1186/s10194-018-0861-3. J Headache Pain. 2018. PMID: 29785578 Free PMC article. Review.
References
REFERENCES
-
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990‐2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1211‐1259.
-
- GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension‐type headache, 1990‐2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17:954‐976.
-
- Tajti J, Szok D, Majláth Z, Tuka B, Csáti A, Vécsei L. Migraine and neuropeptides. Neuropeptides. 2015;52:19‐30.
-
- Sacco S, Amin FM, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention ‐ 2022 update. J Headache Pain. 2022;23:67.
-
- Guo S, Jansen‐Olesen I, Olesen J, Christensen SL. Role of PACAP in migraine: an alternative to CGRP? Neurobiol Dis. 2022;176:105946.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical